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Lectin-like oxidized low-density lipoprotein
receptor-1
ATP-binding cassette transporter A/G1a b s t r a c t
Dickkopf1 (DKK1), a canonical Wnt/b-catenin pathway antagonist, is closely associated with cardio-
vascular disease and adipogenesis. We performed an in vitro study to determine whether oxidized
low-density lipoprotein (ox-LDL) increased the expression of DKK1 in macrophages and whether b-
catenin and liver X receptor a (LXRa) were involved in this regulation. Induction of DKK1 expression
by ox-LDL decreased the level of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) via a
Wnt/b-catenin pathway and increased ATP-binding cassette transporter A/G1 (ABCA/G1) levels via a
signal transducer and activator of transcription 3 (STAT3) pathway. Lower LOX-1 and higher ABCA/
G1 levels inhibited cholesterol loading in macrophages. In conclusion, ox-LDL may induce DKK1
expression in macrophages to inhibit the accumulation of lipids through a mechanism that involves
downregulation of LOX-1-mediated lipid uptake and upregulation of ABCA/G1-dependent
cholesterol efﬂux.
 2014 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Oxidized LDL (ox-LDL) is associated with the pathogenesis of
various human diseases, such as atherosclerosis, aortic valve steno-
sis [1] and age-related macular degeneration [2]. Monocytes in the
blood roll and adhere to the arterial wall, migrate into the
subendothelial space, and differentiate into macrophages, which
internalize ox-LDL and other pathogenic debris [3] to reduce the
toxicity of ox-LDL. Foam cells formed by macrophages play a key
and complicated role in atherosclerosis. For instance, in the forma-
tion of early ‘‘fatty streaks’’, monocyte-derivedmacrophages loaded
with lipids are transformed into foam cells. Successive accumula-
tion of lipids in macrophages leads to apoptosis and necrosis.
The wingless (Wnt) signaling pathway is a conserved pathway
involved in embryonic development and regulating cell
differentiation, proliferation and migration [4]. Many diseases
related to an abnormal Wnt pathway include degenerative
diseases (Alzheimer’s disease) [5], malignant diseases (multiple
myeloma) [6], systemic diseases (rheumatoid arthritis) [7] andchronic diseases (atherosclerosis) [8]. The Wnt pathway as a mod-
ulator in disease is a current focus.
The Dickkopf-related protein family is secreted in antagonism to
the Wnt pathway. Dickkopf1 (DKK1) has been widely reported.
DKK1 cuts off theWnt pathway and decreases the downstream tar-
get genes of b-catenin, such as cyclinD1, C-Myc, and peroxisome
proliferator-activated receptor d [8]. Previous studies showed
DKK1 involved in cardiovascular diseases such as cardiogenesis
[9], vascular calciﬁcation [10], and angiogenesis [11]; it also pro-
motes theendothelial–mesenchymal transition in aortic endothelial
cells [12]. DKK1 has an antiﬁbrotic role inmicrovascularmural cells
[13]. It is a mediator in platelet-mediated endothelial cell activation
in atherosclerosis [14]. Our recent study showed a higher baseline
plasma level ofDKK1 inpatientswith ST-segment elevationmyocar-
dial infarction as comparedwith patientswith non-ST-segment ele-
vation acute coronary syndrome, and the rate of major adverse
cardiac events was associated with increased DKK1 level [15].
Liver X receptor a (LXRa) is a nuclear receptor that plays an
important role in maintaining cholesterol homeostasis. The activa-
tion of LXRa increases reverse cholesterol transport in macro-
phages by upregulating ATP-binding cassette transporter A/G1
(ABCA/G1) as its target gene [16]. Both ABCA1 and ABCG1 are
members of the large superfamily of ABC transmembrane
transporters, responsible for cellular cholesterol efﬂux. However,
whether DKK1 has any effects on lipid accumulation by ABCA/G1
has not yet been studied.
Fig. 1. Effect of ox-LDL oxidized low-density lipoprotein (ox-LDL) on DKK1 release in macrophages derived from THP-1 cells. (A–C) After stimulation with PMA (160 nM),
THP-1 cells differentiated into macrophages were incubated with different concentrations of ox-LDL for various times. Shows western blot (A, B) and RT-PCR (C) analysis of
protein and mRNA levels of DKK1 in macrophages. (D) ELISA of DKK1 secretion in cell culture medium. One-way ANOVA with LSD post hoc test, n = 3.
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phages remain unclear. To determine the role and regulation of
DKK1 in lipid metabolism, we examined the regulation of DKK1
by ox-LDL and its function in lipid accumulation and the underly-
ing mechanisms.
2. Materials and methods
2.1. Materials
Recombinant human DKK1 (rDKK1) and human DKK1 ELISA kit
were from R&D Systems (Minneapolis, MN, USA). Antibodies for
phosophorylated-b-catenin (p-b-catenin), b-catenin, cyclinD1, p-
signal transducer and activator of transcription 3 (p-STAT3), STAT3,
b-actin and GAPDH were from Cell Signaling Technology (Danvers,
MA, USA). Antibody for ABCG1 and protein A/G plus agarose were
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies
for ABCA1, DKK1, LXRa and LXRb were from Abcam (Cambridge,
UK). Antibody for lectin-like oxidized low-density lipoprotein
receptor-1 (LOX-1) was from Epitomics (Hangzhou, China). Gera-
nylgeranyl pyrophosphate (GGPP), 22-(S)-hydroxycholesterol and
22-(R)-hydroxycholesterol were from Sigma (St. Louis, MO, USA).
T0901317, GW3965 and Stattic were from Selleckchem (Shanghai).
DiI-labeled ox-LDL (DiI-ox-LDL) and ox-LDL were from Yiyuan Bio-
technologies (Guangzhou, China).
2.2. Cell culture
THP-1 cells obtained from the American Type Culture Collection
(ATCC) were grown in RPMI 1640 medium with 10% fetal bovine
serum and 1% penicillin/streptomycin in a 5% CO2-humidiﬁed incu-
bator at 37 C. For THP-1 cell differentiation into macrophages,
cells were seeded in culture plates at 2  106 cells/1 ml per well
and allowed to adhere and differentiate overnight at 37 C in the
presence of 160 nM phorbol myristate acetate (PMA).
2.3. Real-time PCR
The total RNA was extracted from macrophages by use of Tran-
Zol reagent. cDNA was prepared from 2 lg RNA with PrimeScript
RT reagent kit (Takara Bio Inc.; Otsu, Shiga, Japan). Real-time PCR
involved use of the SYRB Premix Ex Taq kit (Takara Bio Inc.). The
primer sequences were for DKK1, forward, 50-GGGAATTACTGCAAAAATGGAATA-30, reverse, 50-ATGACCGGAGACAAACCAGAAC-30;
and b-actin, forward, 50-CGTGCGTGACATTAAGGAGA-30, reverse,
50-CACCTTCACCGTTCCAGTTT-30. The 2DDCt method was used to
assess the relative mRNA expression level normalized to that of
b-actin.
2.4. Western blot analysis
Cells were lysed with RIPA lysis buffer including 1 mM PMSF.
Equal amounts of extracted proteins were separated on 10% SDS–
PAGE gel and transferred to PVDF membranes for incubation with
primary antibodies overnight at 4 C. The bands were visualized by
enhanced chemiluminescence reagents and recorded by use of the
LAS-4000 luminescent image analyzer (Fujiﬁlm, Stamford, CT,
USA).
2.5. Enzyme-linked immunosobent assay (ELISA)
THP-1 differentiated macrophages were stimulated with or
without ox-LDL, and medium was collected and frozen at 80 C.
DKK1 in the supernatant was measured by ELISA assay according
to the manufacturer’s instruction.
2.6. RNA interference
Macrophages cultured with antibiotic-free medium were trans-
fected with speciﬁc siRNA or negative control siRNA (GenePharma,
shanghai) by using Lipofectamine 2000. After 6 h, complete culture
medium was replaced. Gene silencing efﬁciency was determined
by western blot analysis.
2.7. Foam cell formation and Dil-ox-LDL uptake assay
Differentiated THP-1 cells were cultured on slides and loaded
with ox-LDL. After siRNA transfection or rDKK1 incubation, cells
were ﬁxed with 4% paraformaldehyde and stained with Oil Red O
and counterstained with hematoxylin. Images were obtained by
light microscopy to assess foam cell formation.
Dil-ox-LDL, labeled with red ﬂuorescence, has been used to
measure ox-LDL uptake by macrophages. Differentiated THP-1
cells were cultured on Lab-Tek II chamber slides and loaded with
DiI-ox-LDL. After siRNA transfection or rDKK1 incubation, cells
were ﬁxed with 4% paraformaldehyde and counterstained with
Fig. 2. The interaction of liver X receptor a (LXRa) and b-catenin is involved in ox-
LDL regulation of DKK1. (A) Western blot analysis of siRNA knockdown of b-catenin
and cyclinD1 in macrophages differentiated from THP-1 cells. (B) Level of DKK1
regulated by ox-LDL (100 mg/L) with or without b-catenin siRNA. (C, E, G) Cells
were pretreated with DMSO or T0901317 (5 lM), GW3965 (1 lM), or 22-(R)-
hydroxycholesterol (10 lM), then incubated with 100 mg/L ox-LDL for 6 h. (D, F)
Cells were pretreated with GGPP (10 lM), 22-(S)-hydroxycholesterol (10 lM) or
ox-LDL (100 mg/L) to mimic the inhibition of LXRa activity by ox-LDL. (H) Western
blot analysis of DKK1 with knockdown of LXRa by siRNA. One-way ANOVA with
LSD post hoc test, n = 3–4.
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tation and 565 nm emission.
2.8. Immunoprecipitation
Differentiated THP-1 cells were incubated with or without ox-
LDL, then lysed with lysis buffer for western blot analysis and
immunoprecipitation. Cell lysates were precleared and incubated
with cognate antibodies and 50% protein A/G agarose overnight
at 4 C with gentle rotation. Agarose-bound immunoprecipitates
were rinsed and underwent SDS–PAGE (2) before western blot
analysis.
2.9. Statistical analysis
All experiments were repeated at least 3 times. Data are pre-
sented as mean ± S.E.M. Data analysis involved unpaired t-test
and one-way ANOVA with LSD post hoc test. P < 0.05 was consid-
ered statistically signiﬁcant.
3. Results
3.1. Ox-LDL upregulates the expression of DKK1 in macrophages
To investigate the effect of ox-LDL on DKK1 in macrophages,
cells were stimulated with different concentrations of ox-LDL for
different times. Stimulation with 100 mg/L ox-LDL signiﬁcantly
increased both the protein and mRNA expression of DKK1 at 6 h
(Fig. 1A–C, P < 0.05) and signiﬁcantly increased the secretion of
DKK1 in culture medium at 9 h (Fig. 1D, P < 0.05). Therefore, ox-
LDL at 100 mg/L for 6 h was used in subsequent experiments.
3.2. Interaction of LXRa and b-catenin is responsible for ox-LDL-
upregulated DKK1
To further investigate the regulation of DKK1 by ox-LDL, we
blocked the expression of b-catenin in macrophages by siRNA
(Fig. 2A, P < 0.05). We also detected the level of cyclinD1 as the tar-
get gene of b-catenin to reﬂect the blockage of the canonical Wnt
pathway. b-catenin siRNA knockdown reduced the ox-LDL-
increased protein level of DKK1 in macrophages (Fig. 2B,
P < 0.05). LXRa agonists can increase the expression of ABCG1 to
accelerate cholesterol efﬂux [17]. Pretreatment with the LXRa ago-
nists T0901317, GW3965 and 22-(R)-hydroxycholesterol abolished
the ox-LDL-increased DKK1 expression (Fig. 2C, E, G, P < 0.05). The
LXRa antagonists GGPP and 22-(S)-hydroxycholesterol increased
the expression of DKK1, which resembled the upregulation of
DKK1 by ox-LDL (Fig. 2D and F, P < 0.05). Knocking down LXRa
level by siRNA increased the level of DKK1 as well (Fig. 2H,
P < 0.05).
LXRa was reported to suppress the transactivation of b-catenin
by directly binding with b-catenin [18]. To conﬁrm the interaction
of LXRa and b-catenin, immunoprecipitation assay revealed that
ox-LDL stimulation decreased the interaction of LXRa and b-cate-
nin (Supplementary Fig. S1A). We also explored the function of
LXRb and found that it had no signiﬁcant effect on regulation of
DKK1 by ox-LDL (Supplementary Fig. S1B and S1C, P > 0.05). These
results suggested that ox-LDL upregulated the level of DKK1 by
decreasing the repression of LXRa on b-catenin.
3.3. DKK1 inhibits lipid accumulation and foam cell formation in
macrophages
We evaluated the effect of DKK1 on lipid accumulation in mac-
rophages. After DKK1 knockdown with siRNA, cells were treated
with 100 mg/L ox-LDL. Intracellular lipid droplet accumulation
Fig. 3. Effect of DKK1 on foam cell formation in macrophages. (A) Cells were transfected with DKK1 siRNA or scrambled siRNA, then incubated with 100 mg/L ox-LDL.
Internalization of ox-LDL was detected by Oil Red O staining. (B) Confocal microscopy of macrophages transfected with DKK1 siRNA, then Dil-ox-LDL (red) added into the cell
medium overnight. DAPI was used to stain nuclei. (C) Cells were incubated with recombinant DKK1 (rDKK1; 100 ng/mL) for 12 h, then 100 mg/L ox-LDL was added to
examine foam cell formation. (D) Macrophages were pretreated with rDKK1 (100 ng/mL) for 12 h, then incubated with Dil-ox-LDL overnight in the dark. Unpaired t-test, n = 3.
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trol (Fig. 3A, P < 0.05). To conﬁrm our ﬁndings, confocal microscopy
revealed that DKK1 siRNA knockdown signiﬁcantly increased
intracellular DiI-ox-LDL level (Fig. 3B, P < 0.05).
Furthermore, we pretreated cells with 100 ng/mL rDKK1 for
12 h, then 100 mg/L ox-LDL. Intracellular lipid droplet accumula-
tion was decreased (Fig. 3C, P < 0.05) as was intracellular DiI-ox-
LDL level (Fig. 3D, P < 0.05), so DKK1 inhibited lipid accumulation
and foam cell formation in macrophages.
3.4. Effect of DKK1 on Wnt/b-catenin pathway in macrophages
To test the inhibition of DKK1 on the Wnt/b-catenin pathway in
macrophages, we examined the level of total b-catenin and its phos-
phorylation after DKK1 siRNA transfection or rDKK1 pretreatment.
DKK1 siRNA knockdown increased the expression of b-catenin and
decreased its phosphorylation in macrophages (Fig. 4A, P < 0.05),
which was in contrast with the effects of rDKK1 (Fig. 4B, P < 0.05).
Then we treated cells with b-catenin siRNA to mimic the inhibition
of DKK1 on the Wnt//b-catenin pathway. Intracellular lipid droplet
accumulation and DiI-ox-LDL level were both decreased with
b-catenin siRNA knockdown (Fig. 4C and D, P < 0.05), so DKK1
suppressed lipid accumulation in part via aWnt/b-catenin pathway.
3.5. DKK1 affects the expression of LOX-1 and ABCA/G1 via a Wnt and
STAT3 pathway, respectively
LOX-1 and ABCA/G1 are closely related to lipid metabolism,
which has an important role in the progression of atherosclerosis.
We found that rDKK1 abolished the ox-LDL-increased expressionof LOX-1 (Fig. 5A, P < 0.05) and DKK1 siRNA knockdown increased
the expression (Supplementary Fig. S2). We treated cells with b-
catenin siRNA to mimic the inhibition of the Wnt pathway by
DKK1. b-catenin siRNA knockdown blocked the ox-LDL-increased
expression of LOX-1, which resembled the rDKK1 effect (Fig. 5B,
P < 0.05).
A STAT-binding site in the ABCA1 promoter at 350 bp [19]
offers a potential link of the STAT3 pathway to ABCA/G1. However,
whether DKK1 affects the expression of ABCA/G1 or regulation
through the STAT3 pathway has not been reported. Phosphoryla-
tion of STAT3 was increased in macrophages incubated with rDKK1
since 10 min (Supplementary Fig. S3, P < 0.05). To address whether
the upregulation of ABCA/G1 expression by DKK1 was mediated
through an STAT3 pathway, we used Stattic, a selective STAT3
inhibitor, to inhibit STAT3 phosphorylation (Fig. 5C, P < 0.05), and
found a signiﬁcantly impaired effect of rDKK1 on ABCA/G1 expres-
sion (Fig. 5D, P < 0.05). siRNA knockdown of STAT3 expression
resulted in abolished upregulation of ABCA/G1 expression by
rDKK1 (Fig. 5E, P < 0.05).
4. Discussion
In the present study, we found that ox-LDL induced the expres-
sion of DKK1 by decreasing the repression of LXRa on b-catenin.
Here we ﬁrst report the regulation of DKK1 in macrophages by
ox-LDL. Moreover, we provide evidence that DKK1 inhibits the
accumulation of lipids in macrophages by decreasing LOX-1
expression via the Wnt/b-catenin pathway and increasing ABCA/
G1 expression via the STAT3 pathway. Thus, DKK1 in macrophages
may be a negative mediator in lipid metabolism.
Fig. 4. Wnt/b-catenin mediates the regulation of DKK1 in lipid metabolism of macrophages. (A) Western blot analysis of the effect of DKK1 siRNA on protein expression of
DKK1 and total and phosphorylated b-catenin. (B) Western blot analysis of total and phosphorylated b-catenin in cells with rDKK1 treatment and incubated with or without
ox-LDL (100 mg/L). (C and D) Oil Red O staining and confocal microscopy of cells transfected with b-catenin siRNA, then ox-LDL or Dil-ox-LDL added into the cell culture
medium. One-way ANOVA or unpaired t-test, n = 3.
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of the cardiac and vascular system. DKK1 level was found
decreased in obesity-prone rat models, with more lipid accumula-
tion in the decidual zones than in obesity-resistant groups. Overex-
pression of DKK1 in JEG3 cells decreased lipid accumulation and
mRNA content of peroxisome proliferator-activated receptor d
[20]. Previous study found that ox-LDL induced senescence of
retinal pigment epithelial cells and increased the expression of
b-catenin [21]. However, whether DKK1 was involved in
ox-LDL-induced macrophage foam-cell formation was unknown.
Here, we found that ox-LDL increased both the protein and mRNA
levels of DKK1 in macrophages.
DKK1 blocks the canonical Wnt/b-catenin pathway via the
combination with LRP5/6 and Kremen on the membrane, which
accelerates phosphorylation of b-catenin in an ubiquitin–protea-
some–mediated manner [22,23]. At the same time, DKK1 is a target
gene of the canonical Wnt/b-catenin pathway, for a negative feed-
back loop [24]. LXR belongs to the nuclear receptor superfamily of
ligand-activated transcription factors and has two isoforms, LXRa
and LXRb. LXRs are activated by forming heterodimers with reti-
noid X receptor and bind to the LXR response element found inthe promoter region of target genes [25]. LXRa has a central role
in lipid metabolism against cholesterol overload by inducing the
transcription of lipid-related genes such as ABCA1 and ABCG1. Pre-
vious studies of LXRs mainly focused on lipid metabolism and
inﬂammation, whereas LXRs are closely related to the Wnt path-
way. In colon cancer HCT116 cells, LXRs regulated b-catenin activ-
ity rather than expression by direct binding [18]. Although we
found that ox-LDL did not affect the expression of LXRa (Supple-
mentary Fig. S4), the effects of LXRa and b-catenin on DKK1
induced by ox-LDL were conﬁrmed by using gene silencing or
pharmacological agonists, whereas gene silencing of LXRb had no
such an effect (Supplementary Fig. S1C). In addition, LXRa bound
with b-catenin in macrophages, which was attenuated by ox-LDL
treatment (Supplementary Fig. S1A). Thus, our results show that
ox-LDL upregulated DKK1 by decreasing the repression of LXRa
on b-catenin.
DKK1 has wide and complex effects on cell proliferation and dif-
ferentiation. DKK1 is involved in many human systemic diseases,
such as rheumatic arthritis, Alzheimer disease [26] and cancers.
Nevertheless, the role of DKK1 in different cancers is diverse. A
high level of DKK1 in multiple myeloma [27] and human
Fig. 5. Wnt and STAT3 pathways mediate the regulation of LOX-1 and ABCA/G1 by
DKK1, respectively. Western blot analysis of protein level of LOX-1 in macrophages
(A) incubated with rDKK1 (100 ng/mL) for 12 h and (B) with b-catenin siRNA
knockdown before adding 100 mg/L ox-LDL. (C and D) Western blot analysis of p-
STAT3, total STAT3, ABCA1 and ABCG1 levels in cells pretreated with DMSO or
Stattic (10 lM) for 1 h before and during stimulation with rDKK1 and (E) in cells
transfected with STAT3 siRNA or negative control, and rDKK1 added into the
supernatant. One-way ANOVA with LSD post hoc test, n = 3–6.
Fig. 6. An intrinsic mechanism for DKK1 inhibiting lipid accumulation in macro-
phages. Ox-LDL increases the levels of DKK1 by decreasing the repression of LXRa
on b-catenin. DKK1 activates the STAT3 pathway and blocks the Wnt/b-catenin
pathway, which increases the levels of ABCA/G1 and decreases that of LOX-1. This
process accelerates lipid efﬂux and attenuates lipid uptake, for reduced lipid
accumulation in macrophages.
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sis. High serum DKK1 level in patients with multiple myeloma was
related to osteolytic lesions [6]. However, inhibiting oncogenic
Wnt/b-catenin induced DKK1 as a suppresser in colon cancer
[28]. Regardless, the function of DKK1 in lipid metabolism of
macrophages is still unknown. We found that DKK1 inhibited
intracellular lipid accumulation and Dil-ox-LDL uptake. Our ﬁnd-
ings suggest that DKK1 inhibition of lipid metabolism involves
inhibiting the canonical Wnt/b-catenin pathway.
Cholesterol accumulation in macrophages results from
imbalanced cholesterol inﬂux and efﬂux. As main receptors and
regulators for lipid metabolism, LOX-1 transports ox-LDL into
differentiated macrophages and ABC transporters use ATP as an
energy source for efﬂux of intercellular cholesterol. Both ABCG1
and secreted frizzled-related protein 2 were upregulated onmicroarray assay of lymphedema tissue, which indicates a poten-
tial cross-talk between the ABC family andWnt proteins [29]. Here,
we found that DKK1 reduced the expression of LOX-1 and
increased that of ABCA/G1, which agrees with DKK1 inhibiting
lipid accumulation in macrophages.
The phenomenon that DKK1 inﬂuences the receptors of lipid
metabolism raised the question of the signaling pathway involved.
The TCF/LEF-1 binding site in the LOX-1 promoter mediates the
canonical Wnt/b-catenin pathway in hepatic stellate cells [30],
and DKK1 leads to the phosphorylation and destabilitation of b-
catenin to block the canonical Wnt pathway. Here, by using gene
silencing of b-catenin, we found that DKK1 repressed the level of
LOX-1 via a Wnt/b-catenin pathway. Mammalian Wnt5a orthologs
may be STAT3-target genes [31]. STAT3 may be a direct target of a
b-catenin–TCF/LEF complex [32]. Duplin, a negative regulator of
the Wnt pathway, represses STAT3 activity [33]. This evidence
shows a cross-link between STAT3 and the Wnt pathway. More-
over, STAT3 signaling in the ABCG1-deﬁcient endothelium was
found responsible for monocyte–endothelial cell interactions
[34]. ABCA1 contains a well-conserved STAT3 element located in
its ﬁrst intron [35]. Hence, we focused on whether DKK1 inﬂu-
enced the expression of ABCA/G1 in macrophages via a STAT3 sig-
naling pathway. Indeed, we found DKK1-increased ABCA/G1 level
abolished by silencing STAT3 expression or inactivating p-STAT3.
We found that DKK1 enhances the capacity of human macro-
phages to maintain cholesterol homeostasis. People on a high-fat
diet are at increased risk of hypercholesterolemia and atheroscle-
rosis. Macrophages in the arterial wall internalize ox-LDL and are
transformed into foam cells, which lead to atherosclerotic plaque
formation and progression [36]. Intracellular excessive lipid accu-
mulation may increase the expression of DKK1 in macrophages,
which inhibits the phagocytosis of lipids, especially ox-LDL, in
human macrophages, for a negative feedback. Our data show the
beneﬁcial effects of DKK1 on lipid metabolism, which has an
important role in atherosclerosis. Previous study showed that
DKK1 enhances the inﬂammatory interaction between platelets
and endothelial cells [14]. Therefore, DKK1 may have various
effects on atherosclerosis depending on the circumstances and
stages. The signiﬁcance of DKK1 in atherosclerosis warrants further
investigation.
58 Y. Zhang et al. / FEBS Letters 589 (2015) 52–58In summary, our study suggests that ox-LDL increases the
expression of DKK1 in macrophages by decreasing the repression
of LXRa on b-catenin (Fig. 6). DKK1 affects lipid metabolism to
decrease the level of LOX-1 and increase that of ABCA/G1 via
Wnt/b-catenin and STAT3 pathways, respectively. Ox-LDL induces
the expression of DKK1 in macrophages, which inhibits lipid accu-
mulation in macrophages.
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